Cell Transplant. 2013;22 Suppl 1:S93-9. doi: 10.3727/096368913X672145. Epub 2013 Aug 29.
The aim of this study is to explore the safety and therapeutic effect of multiple cell transplantations on patients with multiple system atrophy. Ten patients suffering from multiple system atrophy were treated by multiple cell transplantations from August 2005 to March 2011. They were six males and four females, with an average age of 51.90 ± 12.92 years (23-66 years). Multiple cell types were transplanted by intravenous, intrathecal, and intracranial routes; for example, 0.4-0.5 × 10(6)/kg umbilical cord mesenchymal cells by intravenous drip, intrathecal implantation of 2.0 × 10(6) Schwann cells and 2.0-5.0 × 10(6) neural progenitor cells through cerebellar cistern puncture, or 2 × 10(6) olfactory ensheathing cells and 4 × 10(6) neural progenitor cells injected into key points for neural network restoration (KPNNR). The neurological function was assessed before and after treatment with the International Cooperative Ataxia Rating Scale (ICARS) by the World Federation of Neurology and the Unified Multiple System Atrophy Rating Scale (UMSARS). The patients achieved neurological function amelioration after treatment, which included improvements in walking ability, gaits, standing, speech, and muscular tension; the ICARS score decreased from a preoperative 46.30 ± 14.50 points to postoperative 41.90 ± 18.40 points (p = 0.049). The UMSARS score decreased from preoperative 50.00 ± 20.65 points to postoperative 46.56 ± 23.05 points (p = 0.037). Among them, two patients remained stable and underwent a second treatment 0.5-1 year after the first therapy. After treatment, five patients were followed up for more than 6 months. Balance and walking ability improved further in four patients, while one patient remained stable for over 6 months. In conclusion, a strategy of comprehensive cell-based neurorestorative therapy for patients with multiple system atrophy is safe and appears to be beneficial. This manuscript is published as part of the International Association of Neurorestoratology (IANR) supplement issue of Cell Transplantation.
本研究旨在探讨多细胞移植治疗多系统萎缩患者的安全性和疗效。2005 年 8 月至 2011 年 3 月,对 10 例多系统萎缩患者进行了多细胞移植治疗。其中男 6 例,女 4 例;年龄 23-66 岁,平均 51.90±12.92 岁。多细胞类型通过静脉、鞘内和颅内途径移植;例如,静脉滴注 0.4-0.5×10(6)/kg 脐带间充质细胞,通过小脑延髓池穿刺植入 2.0×10(6)施万细胞和 2.0-5.0×10(6)神经祖细胞,或向神经网络修复关键点(KPNNR)注射 2×10(6)嗅鞘细胞和 4×10(6)神经祖细胞。采用世界神经病学联合会国际合作共济失调评分(ICARS)和统一多系统萎缩评分(UMSARS)对治疗前后的神经功能进行评估。患者治疗后神经功能改善,包括行走能力、步态、站立、言语和肌张力改善;ICARS 评分从术前 46.30±14.50 分降至术后 41.90±18.40 分(p=0.049)。UMSARS 评分从术前 50.00±20.65 分降至术后 46.56±23.05 分(p=0.037)。其中 2 例患者病情稳定,在第一次治疗后 0.5-1 年进行了第二次治疗。治疗后,5 例患者随访超过 6 个月。4 例患者的平衡和行走能力进一步改善,1 例患者在 6 个月以上时间内保持稳定。综上所述,多系统萎缩患者的综合细胞神经修复治疗策略是安全的,且可能有益。本文作为国际神经修复学会(IANR)细胞移植增刊的一部分发表。